Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation.
Falcone M, Tiseo G, Marchetti G, Kalo J, Galfo V, Occhineri S, Almerigogna F, Matucci T, Riccardi N, Suardi LR, Rina I, Sijoni L, Caparello MC, Cassano Cassano R, Del Giudice ML, Franciosa M, Facella F, Tancredi G, Fazzi R, Galimberti S.
Falcone M, et al. Among authors: cassano cassano r.
Leuk Lymphoma. 2024 Oct;65(10):1474-1481. doi: 10.1080/10428194.2024.2361099. Epub 2024 Jun 4.
Leuk Lymphoma. 2024.
PMID: 38832710